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Active Bacterial Core Surveillance (ABCs) Report 
Emerging Infections Program Network 
Methicillin-Resistant Staphylococcus aureus, 2013
ABCs Areas 
California (3 county San Francisco Bay area); Colorado (5 county Denver area); Connecticut; Georgia (8 county Atlanta area); Maryland (Baltimore 
City and County); Minnesota (2 metro Twin City counties); New York (1 Rochester county); Oregon (3 county Portland area); Tennessee (1 Nashville 
county).   
 
ABCs Population 
The surveillance areas represent 19,842,441 persons 
Source: National Center for Health Statistics bridged-race vintage 2013 postcensal file.   
 
ABCs Case Definition 
Invasive methicillin-resistant Staphylococcus aureus (MRSA) disease:  isolation of MRSA from a normally sterile site in a resident of the surveillance 
area in 2013.  Cases of disease are classified into one of three epidemiologic classifications.  A case is classified as hospital-onset (HO) if the MRSA 
culture was obtained on or after the fourth calendar day of hospitalization, where admission is hospital day 1;  as healthcare-associated community-
onset (HACO) if the culture was obtained in an outpatient setting  or before the fourth calendar day of hospitalization and had one or more of the 
following: 1) a history of hospitalization, surgery, dialysis, or residence in a long term care facility in the previous year, or 2) the presence of a central 
vascular catheter (CVC) within 2 days prior to MRSA culture; and as community-associated (CA) if none of the previously mentioned criteria are met. 
 
ABCs Methodology 
ABCs personnel routinely contacted all microbiology laboratories serving healthcare facilities in their area to identify cases. Standardized case report 
forms that include information on demographic characteristics, clinical syndrome, and outcome of illness were completed for each identified case.  
Convenience samples of isolates were collected and sent to CDC for routine testing, including antimicrobial susceptibility testing, toxin testing, 
SCCmec typing, and spa typing. Pulsed field gel electrophoresis (PFGE) of all isolates was discontinued in 2008; up until 2012, PFGE was inferred based 
on a validated algorithm (http://www.cdc.gov/HAI/settings/lab/inferred-PFGE-algorithm.html).  Starting in 2012, spa typing was added to the routine 
laboratory testing.  Pulsed field type is currently inferred based on spa type, inferred MLST clonal complex and molecular characteristics of the isolates 
(http://www.cdc.gov/HAI/settings/lab/CCalgorithm.html).  In 2013, isolates were only collected in five sites (California, Georgia, Minnesota, New 
York, and Tennessee). Regular laboratory audits were performed to ensure completeness of case detection. 
 
Rates of invasive MRSA disease among all patients were calculated using population estimates for 2013.  Cases with unknown race were assigned 
race based on distribution of known age, race, and gender by EIP site.  Confidence intervals for nationally estimated incidence rates of disease and 
mortality were calculated based on the gamma distribution (Stat Med, 1997 16:791-801).   
 
Rates of invasive MRSA disease among patients who were undergoing chronic dialysis treatment were calculated using the December 31, 2012 point 




















Reported Race among 4576 Cases 
Race                               No.    (Rate a)           
White  2843 (20.6) 
Black  1563   (40.6) 
Other  170 (7.9) 
 
Unknown race (n=390) distributed amongst known 
a Cases per 100,000 population for ABCs areas (crude rates) 
Cases, Deaths & Inferred PFGE  type by Epidemiological Classification 
MRSA 
Class 
No. (Rate)  
Cases b 
No. (Rate)  
Deaths c 
Inferred PFGE Type (%) 
Tot N USA100 USA300 
USA500/ 
Iberian 
CA 998 (5.0) 102 (0.5) 150 22 (14.7) 103 (68.7) 6 (4.0) 
HCA a 3529 (17.8) 480 (2.4) 554 243 (43.9) 165 (29.8) 75 (13.5) 
HO 704 (3.6) 135 (0.7) 111 48 (43.2) 41 (36.9) 9 (8.1) 
HACO 2825 (14.2) 345 (1.7) 443 195 (44.0) 124 (28.0) 66 (14.9) 
a HCA: Healthcare-associated invasive MRSA infection; sum of patients that are classified 
as  either the HO or HACO classes 
b n= 49 epidemiologic category unknown 
c n=6;  epidemiologic category unknown 
 
Reported Cases on Chronic Dialysis (n=872) 
Dialysis and Access Type No.   (%) 
Type of dialysis   
      Peritoneal  29 (3.3) 
      Hemodialysis  834 (95.6) 
AV Fistula/Graft 340 (39.0) 
CVC 462 (53.0) 
Unknown 32 (3.7) 
      Unknown  9 (1.0) 
 



































 No. (%) No. (%) No. (%) 
Bloodstream Infection b    
with other syndrome 521 (52.2) 1363 (48.2) 216 (30.7) 
with no other syndrome 210 (21.0) 963 (34.1) 247 (35.1) 
Pneumonia 141 (14.1) 349 (12.4) 95 (13.5) 
Lower Respiratory Infection c 44 (4.4) 103 (3.6) 28 (4.0) 
Osteomyelitis 154 (15.4) 418 (14.8) 142 (20.2) 
Endocarditis 75 (7.5) 168 (5.9) 29 (4.1) 
Cellulitis 180 (18.0) 233 (8.2) 56 (8.0) 
Wounds     
Surgical d 8 (0.8) 136 (4.8) 28 (4.0) 
Decubitus/Pressure Ulcers 10 (1.0) 53 (1.9) 11 (1.6) 
Skin Abscesses e 94 (9.4) 87 (3.1) 18 (2.6) 
Other Woundsf 32 (3.2) 96 (3.4) 32 (4.5) 
Traumatic 11 (1.1) 6 (0.2) 3 (0.4) 
a Some case patients had more than one syndrome. 
b Catheter site infection or AV fistula infection only are included in BSI with other syndrome. 
c Lower Respiratory Infection is defined as:  a patient with pneumonia documented in their discharge summary who has 
a positive MRSA non-sterile respiratory specimen with accompanying chest radiology results documenting any of the 
following: bronchopneumonia/pneumonia, air space density/opacity, new or changed infiltrates. 
d Combines deep tissue/organ infection and infection of a surgical wound, post operatively. 
e Category includes skin abscess, necrotizing fasciitis, gangrene. 
fCategory includes non-traumatic and other chronic wound infections. 
 
National Estimates and Adjusted Incidence Rates of Invasive MRSA Infections 
Epidemiologic 
Category 
Estimated Cases of Infection 
Non-Dialysis Patients Dialysis Patients Total 
 Estimated 
No. 
Incidence Rate  
(Confidence Interval) a 
Estimated 
No. 
Incidence Rate  




(Confidence Interval) d 
CA 16,117 5.10 (3.92-6.74) NA NA 16,117 5.10 (3.92-6.74) 
HCA 43,864 13.90 (12.02-16.23) 13,919 3079.89 (2331.21-4076.80) 57,783 18.28 (15.34-22.04) 
      HO 9,820 3.11 (2.24-4.39) 1,584 350.44  (153.54-710.62) 11,404 3.61 (2.46-5.40) 
      HACO 34,044 10.78 (9.21-12.76) 12,335 2729.00 (2026.78-3681.88) 46,379 14.67 (12.10-18.00) 
Overall c 60,772 19.25 (16.94-22.05) 13,921 3079.89 (2331.21-4076.80) 74,693 23.63 (20.24-27.84) 
a National Estimates and Incidence (no. per 100,000 population per year) are adjusted for age,  race, gender and receipt of chronic dialysis using 2013 US Census Data.  
b National Estimates and Incidence (no. per 100,000 dialysis patients per year) for dialysis patients are adjusted for age, race and gender using 2012 USRDS point prevalence data.   
c 49 cases could not be classified into an epidemiological category or category is unknown and therefore are counted in the overall estimate only.   
d Starting in 2011, confidence intervals on national estimates were determined for each of the 72 age/race/gender/dialysis specific strata and summarized for an overall national 































Incidence of Invasive MRSA, by
Epidemiological Class and Age Group
2013
CA HACO HO

























Surveillance data from 2013 represent the ninth full year of performing population-based surveillance for invasive MRSA infections through the 
Emerging Infections Program/Active Bacterial Core Surveillance Activity.  
 
Compared to 2012, incidence of healthcare-associated MRSA decreased by 1.01% while incidence of community-associated MRSA increased by 
6.51%.  Compared to the baseline incidence (2007-2008 calendar years) identified in the HHS Action Plan, there was a decrease of 32.50% for 
healthcare-associated MRSA.  
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National Estimates and Adjusted Incidence Rates for Mortality among Cases 
Epidemiologic Class Estimated No. Mortality Rate 
(Confidence Interval) a 
CA 1,710 0.54 (0.28-1.00) 
HCA 8,150 2.58 (1.68-4.01) 
HO 2,331 0.74 (0.33-1.59) 
HACO 5,819 1.84 (1.12-3.02) 
Overall b 9,937 3.14 (2.14-4.68) 
a National Estimates and Mortality Rate (no. per 100,000 population per year) 
are adjusted for age, race, gender and receipt of chronic dialysis using 2013 US 
Census Data 
b 49  cases could not be classified into an epidemiological category or category is 
unknown and therefore are counted in the overall estimate only. 
 Disease Rate  Estimate of Cases in United States. a 
Baseline (07-08) 2013 % Change Baseline (07-08) 2013 Difference 
HCA  27.08 18.28 -32.50 82,000 58,000 24,000 
a  Disease Rate (no. per 100,000 population per year) and National Estimates are adjusted for age, race, 
gender and receipt of chronic dialysis  using 2012 US Census Data 
 
